Adverse events experienced at short or long term ‐ Serious adverse events 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol showed no clear difference in adverse events experienced at short or long term ‐ Serious adverse… compared with placebo (low certainty).
1 finding from 1 review
Other measures of resolution, as assessed by a clinician, at any · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol showed no clear difference in other measures of resolution, as assessed by a clinician, at any compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of parents who consider their child still has a problem, at any · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of children who consider they still have a problem, at any · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aesthetics · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clearance, as assessed by a clinician at any · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
A subjective measure of improvement, as assessed by the parent or child, at any · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
It is very uncertain whether moxifloxacin changes mortality compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · NSTI
It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
It is very uncertain whether AB103 changes mortality compared with placebo (very low certainty).
1 finding from 1 review
SAEs · NSTI
It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).
1 finding from 1 review
Survival time · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Short‐term clinical cure (up to 3 months after start of treatment) (completely cleared short term) · molluscum contagiosum
Imiquimod showed no clear difference in short‐term clinical cure (up to 3 months after start of treatment)… compared with vehicle (moderate certainty).
1 finding from 1 review